Related Experiment Video
Updated: Jun 4, 2025

High-resolution Time-lapse Imaging and Automated Analysis of Microtubule Dynamics in Living Human Umbilical Vein Endothelial Cells
Published on: August 13, 2016
Microtubule Association of EML4-ALK V3 Is Key for the Elongated Cell Morphology and Enhanced Migration Observed in V3
Savvas Papageorgiou1, Sarah L Pashley1, Laura O'Regan1
1Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, Leicester LE1 7RH, UK.
Abstract:
The EML4-ALK oncogene drives tumour progression in approximately 5% of cases of non-small-cell lung cancers. At least 15 EML4-ALK variants have been identified, which elicit differential responses to conventional ALK inhibitors. Unfortunately, most, if not all, patients eventually acquire resistance to these inhibitors and succumb to the disease, which warrants the need for alternative targets to be identified. The most aggressive variant, EML4-ALK variant 3 (V3), assembles into a complex on interphase microtubules together with the NEK9 and NEK7 kinases, which leads to the downstream phosphorylation of NEK7 substrates. Overall, this promotes an elongated cell morphology and an enhanced migratory phenotype, which likely contributes to the increased metastasis often seen in V3 patients. Here, using two separate approaches to displace V3 from microtubules and a variety of in vitro assays, we show that microtubule association of EML4-ALK V3 is required for both V3 phenotypes, as removal of the oncogenic fusion protein from microtubules led to the dissociation of the V3-NEK9-NEK7 complex and the reversal of both phenotypic changes. Overall, we propose that targeting the interaction between EML4-ALK V3 and microtubules might offer a novel therapeutic option, independent of ALK activity, for V3+ NSCLC patients with acquired resistance to ALK inhibitors.
Insights
Targeting the EML4-ALK variant 3 (V3) oncogene's interaction with microtubules may offer new therapies for non-small-cell lung cancer (NSCLC). Displacing V3 from microtubules reverses aggressive tumor cell phenotypes, suggesting a novel therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The EML4-ALK oncogene drives non-small-cell lung cancer (NSCLC) progression in about 5% of cases.
- Multiple EML4-ALK variants exist, with varying responses to ALK inhibitors, and acquired resistance is a significant clinical challenge.
- EML4-ALK variant 3 (V3) is associated with aggressive disease, forming complexes with NEK9 and NEK7 kinases on microtubules, promoting cell elongation and migration.
Purpose of the Study:
- To investigate the role of EML4-ALK V3's association with microtubules in driving tumor progression.
- To explore therapeutic strategies targeting the microtubule interaction of EML4-ALK V3, independent of ALK kinase activity.
Main Methods:
- Utilized two distinct experimental approaches to detach EML4-ALK V3 from microtubules.
- Conducted various in vitro assays to assess phenotypic changes and complex formation.
- Analyzed the impact of V3 displacement on the V3-NEK9-NEK7 complex and downstream signaling.
Main Results:
- Microtubule association of EML4-ALK V3 is essential for its oncogenic phenotypes, including cell elongation and enhanced migration.
- Displacing EML4-ALK V3 from microtubules disrupted the V3-NEK9-NEK7 complex.
- Reversal of V3-driven phenotypic changes was observed upon V3 removal from microtubules.
Conclusions:
- Targeting the interaction between EML4-ALK V3 and microtubules presents a potential novel therapeutic avenue for V3-positive NSCLC.
- This strategy could be effective for patients who have developed resistance to conventional ALK inhibitors.
- The findings suggest a therapeutic approach independent of ALK kinase inhibition.
Related Concept Videos
Microtubules in Cell Motility
Cytoskeletal Coordination in Cell Migration
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Destabilization of Microtubules
Microtubule Instability
Mechanism of Lamellipodia Formation

